Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06593106 · ClinicalTrials.gov registry record · NA

Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial

A NA study of Stage II Lung Cancer and Stage I Lung Cancer, sponsored by Vanderbilt-Ingram Cancer Center.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06593106 is a NA study of Stage II Lung Cancer and Stage I Lung Cancer that is actively recruiting participants, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 30 participants, below the 102-participant average among 3 other Stage II Lung Cancer trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06593106, a NA study of Stage II Lung Cancer and Stage I Lung Cancer, is actively recruiting participants, sponsored by Vanderbilt-Ingram Cancer Center.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This clinical trial studies side effects and best treatment time of cryodevitalization in treating patients with early stage (stage I or stage II) lung cancer. Cryodevitalization is a type of cryosurgery that uses a flexible probe (cryoprobe) to kill tumor cells by freezing them. It is delivered at the time of standard diagnostic robotic bronchoscopy. Using cryodevitalization may be safe, tolerable and/or effective in treating patients with early stage lung cancer.

Interventions

  • PROCEDURE Chest Radiography
  • PROCEDURE Cryosurgery
  • PROCEDURE Resection
  • PROCEDURE Robotic Bronchoscopy
  • PROCEDURE Bronchoscopy with Biopsy

Study Locations (1)

Tennessee

  • Vanderbilt University/Ingram Cancer Center - Nashville

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-09-27
Est. Completion 2026-08-31
Phase NA

Sponsor

Vanderbilt-Ingram Cancer Center

189 total trials

What the Registry Record Tells You About NCT06593106

The ClinicalTrials.gov registry entry for NCT06593106 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 102-participant average among 3 other Stage II Lung Cancer trials with a reported enrollment target (71% lower). The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Stage II Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Chest Radiography is the first listed.

NCT06593106 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT06593106 about?

NCT06593106 is a clinical study titled "Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial". This clinical trial studies side effects and best treatment time of cryodevitalization in treating patients with early stage (stage I or stage II) lung cancer. Cryodevitalization is a type of cryosurgery that uses a flexible probe (cryoprobe) to kill tumor cells by freezing them. It is delivered at ...

What is the current status of trial NCT06593106?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-09-27. Estimated completion is 2026-08-31.

What conditions does trial NCT06593106 study?

This clinical trial studies the following conditions: Stage II Lung Cancer, Stage I Lung Cancer.

What interventions are being tested in trial NCT06593106?

The interventions under investigation include: Chest Radiography (PROCEDURE), Cryosurgery (PROCEDURE), Resection (PROCEDURE), Robotic Bronchoscopy (PROCEDURE), Bronchoscopy with Biopsy (PROCEDURE).

Who is sponsoring clinical trial NCT06593106?

This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06593106 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stage II Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.